Why interest rates could fall to 0.5% or lower

Share market bulls will be salivating at JP Morgan's prediction that rates will go lower than what most are expecting. But you should be careful for what you wish for.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Share market bulls who have been getting excited by the thought of interest rate cuts will be salivating at JP Morgan's prediction that rates will go lower than what most are expecting.

The market has priced in a 25-basis point cut to the official cash rate at the Reserve Bank of Australia's (RBA) meeting next week and two in the following months.

This expectation is one reason why the S&P/ASX 200 (Index:^AXJO) (ASX:XJO) index has been running hot in recent weeks and has broken above the psychologically important 6,400 level.

Stock valuations typically improve as interest rates drop and that's why some might be particularly enamoured by JP Morgan's call for a fourth rate cut before mid-2020, which would bring the interest rate to a fresh record low of 0.5%!

Be careful what you wish for

But it could be a case of being careful for what you wish for. While lower interest rates are stimulatory, it could come at a high cost. Such a dramatic move by the RBA would be a signal for investors to panic.

The reason behind JP Morgan's non-consensus call is a case in point. The economists at the investment bank is basing their forecasts on the worsening global economic downturn, according to the Australian Financial Review.

If global growth takes a bigger than expected hit from macroeconomic factors like the US-China trade war or a hard Brexit, ASX stocks will sink regardless of the lower interest rate.

RBA could cut rates below 0.5%

Speaking of lower rates, JP Morgan's economist Sally Auld thinks the RBA may not stop at 0.5%. There are a few reasons for this.

Firstly, she doesn't think core inflation in Australia will reach the RBA's target, not when global growth is weakening, even in the US where the economy is performing better than most developed nations.

This could force the US Federal Reserve to cut rates, which would in turn mean the RBA has to lower the cash rate to below 0.5%.

It's not only the absolute level of the interest rate that is important. How it compares to other economies is also fundamental when it comes to stimulating the domestic economy.

The other concern is that real interest rates have been going up. While the RBA has held the cash rate at 1.5% since mid-2016, falling inflation has pushed up the real rate to its highest level in three years. The real rate is the difference between the cash rate and inflation.

The thing that could throw off JP Morgan's forecast is how the newly re-elected federal government will move to shore up the local economy beyond the income tax cuts they have already announced.

Foolish takeaway

I don't think the RBA will cut rates to 0.5%. This isn't because I have a more bullish view on the Australian economy but because of the "diminishing rate of return" theory where the impact of an action becomes more muted the more you do it.

From that perspective, I think lowered the rate from 0.75% to 0.5% won't have the desired impact and the RBA would be better off using "unconventional" measures, such as quantitative easing.

Regardless of whether the RBA cuts three or more times, investors should better appreciate the risks facing our economy. Right now, there's too much optimism factored into our share market, in my view.

Motley Fool contributor Brendon Lau has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Three small children reach up to hold a toy rocket high above their heads in a green field with a blue sky above them.
Growth Shares

These 4 ASX 200 stocks could jump another 70% to 80% in 2026

These stocks are expected to rocket higher.

Read more »

Two excited woman pointing out a bargain opportunity on a laptop.
Share Gainers

3 ASX 200 stocks jumping higher in this week's falling market

Investors shrugged off the broader market retrace and piled into these three ASX 200 stocks this week.

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why EOS, Lotus Resources, REA, and Web Travel shares are dropping today

These shares are ending the week deep in the red. But why?

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Brambles, HMC Capital, ResMed, and Rio Tinto shares are rising today

These shares are avoiding the selloff and are pushing higher on Friday.

Read more »

A woman looks shocked as she drinks a coffee while reading the paper.
Share Fallers

Why is the Web Travel share price crashing 41% on Friday?

ASX investors are pummelling Web Travel shares today. But why?

Read more »

A man looking at his laptop and thinking.
Materials Shares

Rio Tinto shares charge higher after Glencore merger collapses

The parties couldn't come to an agreement.

Read more »

a group of doctors and medical staff in uniform high five in celebration in a hospital setting
Share Market News

Neuren Pharmaceuticals kicks off Phase 3 trial in rare syndrome

Neuren Pharmaceuticals shares are on watch after dosing began in its key Phase 3 trial for Phelan-McDermid syndrome.

Read more »